Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke
Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar
Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
GSK Confirms Rotavirus Vaccine Shortage, Hits Four African Countries: Report
After disruptions at GSK plc (NYSE:GSK), supplies of rotavirus infection vaccine in children have either run out in Kenya, Tanzania,…
Rotavirus Childhood Vaccine Shortage Due to Disruptions at GSK Impacts Four African Countries
-Reuters
https://www.reuters.com/world/africa/exclusive-rotavirus-childhood-vaccine-shortage-hits-four-african-countries-2022-08-10/
Biotech Investors: August’s Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the month were new molecular entities, underlining a lack of innovation going on in the sector.
Recap Of Friday’s Biotech Catalysts – End of The Day Summary
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE…
Daily Biotech Pulse: GSK’s Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion’s Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recap of Wednesday’s Biotech Catalysts – End of The Day Summary
IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate…
GSK Announces U.S. FDA Approval of Benlysta (Belimumab) For Pediatric Patients With Active Lupus Nephritis
GSK plc (NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving